305 related articles for article (PubMed ID: 12194070)
1. Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal.
Newman WD; Tocher K; Acheson JF
Eye (Lond); 2002 Sep; 16(5):567-71. PubMed ID: 12194070
[TBL] [Abstract][Full Text] [Related]
2. The natural history of Vigabatrin associated visual field defects in patients electing to continue their medication.
Best JL; Acheson JF
Eye (Lond); 2005 Jan; 19(1):41-4. PubMed ID: 15094729
[TBL] [Abstract][Full Text] [Related]
3. Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose.
Kinirons P; Cavalleri GL; O'Rourke D; Doherty CP; Reid I; Logan P; Liggan B; Delanty N
Epilepsia; 2006 Feb; 47(2):311-7. PubMed ID: 16499754
[TBL] [Abstract][Full Text] [Related]
4. [Vigabatrin and visual field defects. A Danish material with evaluation of different screening methods].
Riise P; Fledelius HC; Rogvi-Hansen Bà
Ugeskr Laeger; 2003 Mar; 165(10):1034-8. PubMed ID: 12645411
[TBL] [Abstract][Full Text] [Related]
5. Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy.
Conway M; Cubbidge RP; Hosking SL
Epilepsia; 2008 Jan; 49(1):108-16. PubMed ID: 18184224
[TBL] [Abstract][Full Text] [Related]
6. Symptomatic and asymptomatic visual loss in patients taking vigabatrin.
Daneshvar H; Racette L; Coupland SG; Kertes PJ; Guberman A; Zackon D
Ophthalmology; 1999 Sep; 106(9):1792-8. PubMed ID: 10485552
[TBL] [Abstract][Full Text] [Related]
7. [Visual field changes secondary to vigabatrin treatment].
Mauri-Llerda JA; Iñiguez C; Tejero-Juste C; Santos-Lasaosa S; Escalza-Cortina I; Ascaso-Puyuelo J; Abad-Alegría F; Morales-Asín F
Rev Neurol; 2000 Dec 16-31; 31(12):1104-8. PubMed ID: 11205539
[TBL] [Abstract][Full Text] [Related]
8. Is visual field constriction in epilepsy patients treated with vigabatrin reversible?
Schmidt T; Rüther K; Jokiel B; Pfeiffer S; Tiel-Wilck K; Schmitz B
J Neurol; 2002 Aug; 249(8):1066-71. PubMed ID: 12195456
[TBL] [Abstract][Full Text] [Related]
9. Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity.
Lawthom C; Smith PE; Wild JM
Ophthalmology; 2009 Mar; 116(3):565-71. PubMed ID: 19168223
[TBL] [Abstract][Full Text] [Related]
10. Vigabatrin and epilepsy: lessons learned.
Wild JM; Ahn HS; Baulac M; Bursztyn J; Chiron C; Gandolfo E; Safran AB; Schiefer U; Perucca E
Epilepsia; 2007 Jul; 48(7):1318-27. PubMed ID: 17635558
[TBL] [Abstract][Full Text] [Related]
11. [Visual field disturbances in epileptic patients treated with vigabatrin (sevril)].
Gross-Tsur V; Lahat E; Banin E; Shahar E; Shalev R
Harefuah; 2002 Mar; 141(3):247-9, 315. PubMed ID: 11944216
[TBL] [Abstract][Full Text] [Related]
12. Binasal visual field defects are not specific to vigabatrin.
Gonzalez P; Sills GJ; Parks S; Kelly K; Stephen LJ; Keating D; Dutton GN; Brodie MJ
Epilepsy Behav; 2009 Nov; 16(3):521-6. PubMed ID: 19815465
[TBL] [Abstract][Full Text] [Related]
13. [The function of eye and vision system in children and youth treated with vigabatrin--our own experiences].
Pojda-Wilczek D; Emich-Widera E; Herba E; Pojda SM; Marszał E
Klin Oczna; 2005; 107(10-12):654-7. PubMed ID: 16619812
[TBL] [Abstract][Full Text] [Related]
14. Vigabatrin-associated visual field defects in children.
Russell-Eggitt IM; Mackey DA; Taylor DS; Timms C; Walker JW
Eye (Lond); 2000 Jun; 14 ( Pt 3A)():334-9. PubMed ID: 11026995
[TBL] [Abstract][Full Text] [Related]
15. Vigabatrin-attributable visual field defects in patients with intractable partial epilepsy.
Tseng YL; Lan MY; Lai SL; Huang FC; Tsai JJ
Acta Neurol Taiwan; 2006 Dec; 15(4):244-50. PubMed ID: 17214087
[TBL] [Abstract][Full Text] [Related]
16. Retinal nerve fibre layer attenuation: clinical indicator for vigabatrin toxicity.
Moseng L; Sæter M; Mørch-Johnsen GH; Hoff JM; Gajda A; Brodtkorb E; Midelfart A
Acta Ophthalmol; 2011 Aug; 89(5):452-8. PubMed ID: 21251242
[TBL] [Abstract][Full Text] [Related]
17. Visual field constriction in epilepsy patients treated with vigabatrin and other antiepileptic drugs: a prospective study.
Schmitz B; Schmidt T; Jokiel B; Pfeiffer S; Tiel-Wilck K; Rüther K
J Neurol; 2002 Apr; 249(4):469-75. PubMed ID: 11967655
[TBL] [Abstract][Full Text] [Related]
18. Vigabatrin-induced peripheral visual field defects in patients with refractory partial epilepsy.
Sergott RC; Bittman RM; Christen EM; Sagar SM
Epilepsy Res; 2010 Dec; 92(2-3):170-6. PubMed ID: 20951555
[TBL] [Abstract][Full Text] [Related]
19. Retinal nerve fibre layer characteristics with vigabatrin-associated visual field loss--could scanning laser polarimetry aid diagnosis?
Durnian JM; Clearkin LG
Eye (Lond); 2008 Apr; 22(4):559-63. PubMed ID: 17401319
[TBL] [Abstract][Full Text] [Related]
20. Visual field loss in young children and mentally handicapped adolescents receiving vigabatrin.
Werth R; Schädler G
Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):3028-35. PubMed ID: 16799049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
